Substance / Medication

Pamabrom

Overview

Active Ingredient
pamabrom
RxNorm CUI
54365

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Naproxen, paracetamol and pamabrom versus paracetamol, pyrilamine and pamabrom in primary dysmenorrhea: a randomized, double-blind clinical trial.
Ortiz Mario I, Murguía-Cánovas Gabriela, Vargas-López Laura C et al. · Medwave · 2016
PMID: 27813503Observational
Erythema multiforme secondary to dimenhydrinate in a patient with previous similar reactions to pamabrom.
Tan Doreen Su-Yin, Sklar Grant E · Ann Pharmacother · 2014
PMID: 24396093Case Report
Fixed drug eruption caused by pamabrom.
Min J A, Kim H S, Kim H O et al. · Clin Exp Dermatol · 2009
PMID: 19681920Case Report
Serum sickness-like reaction to Pamabrom.
Swanson Jil K, English Joseph C · J Drugs Dermatol · 2006
PMID: 16573265Case Report
Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea?
Di Girolamo Guillermo, Sánchez Adriana J, De Los Santos Antonio Raul et al. · Expert Opin Pharmacother · 2004
PMID: 15013925Review
HPTLC and RP-HPLC methods for simultaneous determination of Paracetamol and Pamabrom in presence of their potential impurities.
Abdelaleem Eglal A, Naguib Ibrahim A, Hassan Eman S et al. · J Pharm Biomed Anal · 2015
PMID: 26001162Other
Effect of nitric oxide-cyclic GMP-Kchannel pathway blockers, naloxone and metformin, on the antinociception induced by the diuretic pamabrom.
Ortiz Mario I, Cariño-Cortés Raquel, Castañeda-Hernández Gilberto et al. · Can J Physiol Pharmacol · 2023
PMID: 36318824Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pamabrom (substance)
SNOMED CT
116552006
UMLS CUI
C0135166
RxNorm CUI
54365

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.